Zacks: Analysts Set $24.50 Price Target for Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (NASDAQ:AQST) has been assigned an average broker rating score of 1.25 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and three have given a strong buy rating to the company. Aquestive Therapeutics’ rating score has improved by 6% from three months ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a 12-month consensus target price of $24.50 for the company and are anticipating that the company will post ($0.91) earnings per share for the current quarter, according to Zacks. Zacks has also given Aquestive Therapeutics an industry rank of 80 out of 256 based on the ratings given to related companies.

AQST has been the topic of a number of recent research reports. Wedbush started coverage on Aquestive Therapeutics in a research note on Wednesday, September 12th. They set an “outperform” rating and a $33.00 target price on the stock. Royal Bank of Canada set a $24.00 price target on Aquestive Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Zacks Investment Research downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 14th. Finally, Lake Street Capital assumed coverage on Aquestive Therapeutics in a report on Thursday. They issued a “buy” rating and a $14.00 target price on the stock.

NASDAQ:AQST traded up $0.82 on Friday, hitting $7.96. The company’s stock had a trading volume of 132,109 shares, compared to its average volume of 97,433. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.42 and a current ratio of 3.63. Aquestive Therapeutics has a one year low of $5.80 and a one year high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.15). The business had revenue of $13.27 million during the quarter, compared to analysts’ expectations of $14.75 million. Equities analysts predict that Aquestive Therapeutics will post -1.15 EPS for the current fiscal year.

In other news, CFO John T. Maxwell acquired 5,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The shares were bought at an average price of $8.87 per share, with a total value of $44,350.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO John T. Maxwell acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 21st. The shares were purchased at an average cost of $9.80 per share, for a total transaction of $98,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 28,650 shares of company stock worth $275,311.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Keybank National Association OH acquired a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at $239,000. Point72 Asset Management L.P. bought a new position in Aquestive Therapeutics during the 3rd quarter worth $350,000. Citadel Advisors LLC bought a new position in Aquestive Therapeutics during the 3rd quarter worth $451,000. Engineers Gate Manager LP bought a new position in Aquestive Therapeutics during the 3rd quarter worth $464,000. Finally, Brant Point Investment Management LLC bought a new position in Aquestive Therapeutics during the 3rd quarter worth $622,000. 64.49% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Read More: Conference Calls and Individual Investors

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit